title: Xuezhikang, extract of red yeast rice, inhibited tissue factor and hypercoagulable state through suppressing nicotinamide adenine dinucleotide phosphate oxidase and extracellular signal-regulated kinase activation.
abstract: Xuezhikang, extract of red yeast rice, is a traditional Chinese medicine with multiple cardioprotective effect. It contains a family of naturally occurring statins, such as lovastatin. Tissue factor (TF) is overexpressed in macrophages of lipid core plaques, which display high procoagulant activity and seem to be a potentially target for anti-atherothrombosis. Therefore, the purpose of this study was to explore the effect and possible molecular mechanisms of xuezhikang on inhibiting TF expression and hypercoagulable state and the differences compared with lovastatin. Our results showed that xuezhikang significantly suppressed oxidized low-density lipoprotein-induced TF expression in macrophages in a concentration-dependent manner. Xuezhikang reduced nicotinamide adenine dinucleotide phosphate oxidase activity by decreasing membrane translocation of p47 through inhibition of extracellular signal-regulated kinase 1/2 activation. Nicotinamide adenine dinucleotide phosphate inhibitor (diphenyleneiodonium) also inhibited the oxidized low-density lipoprotein-induced TF expression, similar to the effects of xuezhikang. Furthermore, consistent with the severity of aortic atherosclerosis, xuezhikang (300 mg·kg·d) significantly reduced blood coagulation activation and TF expression in high-cholesterol diet-induced atherosclerotic rats. In addition, xuezhikang was more potent than lovastatin on inhibiting the expression of TF and nicotinamide adenine dinucleotide phosphate oxidase activation. These observations provide evidences that inhibition of xuezhikang on hypercoagulation and TF expression may partly account for its cardioprotective benefits.
authors.affiliation: From the Department of Geriatrics, Peking University First Hospital, Xicheng District, Beijing, China.
authors.forename: Pei
authors.initials: P
authors.lastname: Li
authors.forename: Yabing
authors.initials: Y
authors.lastname: Yang
authors.forename: Meilin
authors.initials: M
authors.lastname: Liu
mesh_terms: D000818:Animals; D001011:Aorta / Q000473:pathology; D001688:Biological Products; D001780:Blood Coagulation Tests; D002470:Cell Survival; D002762:Cholecalciferol / Q000494:pharmacology; D002784:Cholesterol / Q000097:blood; D059305:Diet, High-Fat; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004789:Enzyme Activation; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000097:blood; D008148:Lovastatin / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000201:enzymology; D008297:Male; D051379:Mice; D019255:NADPH Oxidases / Q000378:metabolism*; D012275:Oryza; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species; D019851:Thrombophilia / Q000188:drug therapy*; D013925:Thromboplastin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014815:Vitamins / Q000494:pharmacology
chemical_list: D001688:Biological Products; D004365:Drugs, Chinese Herbal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D017382:Reactive Oxygen Species; D014815:Vitamins; C117343:red yeast rice; C496822:xuezhikang; D002762:Cholecalciferol; D013925:Thromboplastin; D002784:Cholesterol; D008148:Lovastatin; D019255:NADPH Oxidases; D048049:Extracellular Signal-Regulated MAP Kinases